A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Diffuse Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients

Trial Profile

A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Diffuse Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Cisplatin; Gimeracil/oteracil/tegafur; Oxaliplatin
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Dec 2016 Planned End Date changed from 1 Apr 2016 to 1 Mar 2017.
    • 07 Dec 2016 Planned primary completion date changed from 1 Apr 2015 to 1 Mar 2017.
    • 17 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top